Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema (DME)
Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.
Diabetic macular edema is seen in the later stages of diabetic retinopathy with current conventional therapies targeting local vascular dysfunction.
- Trial name
- NCT07457632
- Testing
- Tauroursodeoxycholate (TUDCA), Traditional Chinese Medicine (mQJDHW)
- Sponsor
- University of Alabama at Birmingham
Diabetes Complications
Retinal Microvasculature by Optical Coherence Tomography Angiography During Integrating Physical Activity in Diabetic Subjects.
Diabetic retinopathy is a common condition of diabetes and can lead to blindness, making it one of the most feared complications of diabetes.
- Trial name
- OCTACTIPH (NCT05645068)
- Testing
- Optical Coherence Tomography Angiography, multidisciplinary care program
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Diffuse Diabetic Macular Edema
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse…
- Trial name
- NCT00999791
- Testing
- Bevacizumab, Diclofenac
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetic Retinopathy
Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
Diabetes affects over 37 million Americans and over 530 million people globally. Each diabetic patient needs at least one retinal exam per year starting immediately at the time of diagnosis if they have Type II diabetes (and…
- Conditions
- Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
- Trial name
- NCT05368623
- Testing
- Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
- Where
- 3 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- RETINA-AI Health, Inc.
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Visual Acuity Reduced Transiently, Macular Edema, Cystoid
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
The aim of the prospective randomized study is to investigate whether a intensified diabetic control program leads to better final visual acuity and less frequent diabetic ocular complications in patients with diabetic…
- Trial name
- DORO (NCT02665689)
- Testing
- ranibizumab
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Prof. Dr. Antonia M. Joussen
Diabetic Macular Edema
Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema
Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.
- Trial name
- LED (NCT03385382)
- Testing
- Dexamethasone intravitreal implant 0.7 mg, Ranibizumab Injection
- Volunteers
- 40 people
- Sponsor
- G. d'Annunzio University
Diabetic Macular Edema
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants…
- Trial name
- RUBY (NCT02712008)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 51 sites in United States
- Volunteers
- 302 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Comparison of Treatments in Diabetic Macular Edema
Prospective or cohort study to compare the effects of grid macular laser, topical bromfenac 0.09% and placebo (carboxymethyl cellulose 0.5%) medication in diabetic macular edema. 60 eyes with macular edema of two types i.e.
- Trial name
- NCT05715385
- Testing
- laser photocoagulation, eye drop bromfenac 0.09%
- Volunteers
- 60 people
- Sponsor
- Babasaheb Ambedkar Memorial Hospital
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied.
- Trial name
- NCT06929143
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Diabetic Macular Edema
Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema
The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).
- Trial name
- NCT02663141
- Testing
- Losartan, Intravitreal bevacizumab
- Where
- Iran
- Volunteers
- 57 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Retinopathy, Diabetic Macular Edema (DME)
AI Prediction of Treatment Response in DME
Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes mellitus. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for…
- Trial name
- NCT07707856
- Testing
- Artificial Intelligence-Based Imaging Analysis
- Where
- Egypt
- Volunteers
- 1,284 people
- Sponsor
- Benha University
Diabetic Retinopathy
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.
- Trial name
- NCT00090519
- Testing
- ruboxistaurin
- Where
- 84 sites in United States, Australia and 15 more
- Volunteers
- 731 people
- Sponsor
- Chromaderm, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Evaluation of Vitrectomy for Diabetic Macular Edema
The study is designed as a prospective cohort study to assess changes in visual acuity and retinal thickening and surgical complications in subjects undergoing vitrectomy for diabetic macular edema.
- Trial name
- Vitrectomy-D (NCT00709319)
- Where
- 48 sites in United States
- Volunteers
- 87 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Diabetic Macular Edema
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Anti-vascular Endothelial Growth Factor
- Trial name
- DR (NCT06272565)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Macular Edema
Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Ranibizumab or combination of Ranibizumab And Dexamethasone under pro re nata treatment regimen for Diabetic Macular…
- Trial name
- NCT04601675
- Testing
- Ranibizumab Ophthalmic and Intravitreal Dexamethasone, Ranibizumab Ophthalmic only
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Eye Hospital
Diabetic Macular Edema
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- KINGLET (NCT04058067)
- Testing
- Brolucizumab, Aflibercept
- Where
- 24 sites in China
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema.
- Trial name
- NCT02193113
- Testing
- KVD001 Injection
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.